COVID-19 and phosphodiesterase enzyme type 5 inhibitors
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Marwa S. Al‐Niemi, Ali K. Albuhadily, Nasser A. Al‐Harchan, Claire Lugnier
Abstract
COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels.
Topics & Concepts
SildenafilCoronavirus disease 2019 (COVID-19)cGMP-specific phosphodiesterase type 5PhosphodiesteraseMedicineEnzymeDiseaseInternal medicineBiologyBiochemistryInfectious disease (medical specialty)Blood Pressure and Hypertension StudiesHeart rate and cardiovascular healthCOVID-19 Clinical Research Studies